FGFR4: Fibroblast growth factor receptor 4
Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on FGFR4, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| FGF401 | Phase 2 | Novartis Pharmaceuticals | Small molecule | InhibitorFibroblast growth factor receptor 4 inhibitor | 0 |
- Cancer0.73
- Urothelial carcinoma0.61
- Rhabdomyosarcoma0.59
- Idiopathic pulmonary fibrosis0.59
- Abnormality of the skeletal system0.58
- Neoplasm0.58
- Cholangiocarcinoma0.58
- Non-small cell lung carcinoma0.58
- Type 2 diabetes mellitus0.57
- Bone development disease0.57
- Interstitial lung disease0.57
- Pulmonary fibrosis0.55
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3973, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P22455, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets